Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors

References

• Diabetes Medical Guidelines Task Force, The American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management – 2002 update. Endocr Pract 2002;8(Suppl 1):40–82
   PubMedGoogle Scholar
• American Diabetes Association. Clinical practice recommendations 2004. Diabetes Care 2004;27(Suppl 1):S1–S150
   Web of Science ®Google Scholar
• ACTOS package insert. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc, December 2003
   Google Scholar
• Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation: a case report. Ann Intern Med 1998;129(1):38–41
   Google Scholar
• Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone [letter]. Ann Intern Med 1999;130:163–4
   PubMed Web of Science ®Google Scholar
• Shibuya A, Watanabe M, Fujita Y, et al. An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care 1998;21:2140–3
   PubMed Web of Science ®Google Scholar
• Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001;7:162–9
   PubMedGoogle Scholar
• Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002;56(4):251–7
   Google Scholar
• King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002;4(2):145–51
   PubMedGoogle Scholar
• Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797–802
   PubMed Web of Science ®Google Scholar
• Einhorn D. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study [The Pioglitazone 027 Study Group]. Clin Ther 2000;22(12):1395–409
   PubMed Web of Science ®Google Scholar
• Aronoff S, Rosenblatt S, Braithwaite S, Egan J, Mathisen A, Schneider R. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes [The Pioglitazone 001 Study Group]. Diabetes Care 2000;23:1605–11
   PubMed Web of Science ®Google Scholar
• Gegick CG, Altheimer MD. Thiazolidinediones (TZD): comparison of long-term effects on lipids [abstract]. Diabetes 2002;51(Suppl 2):A423
   Google Scholar
• Dirani RG, Robert T. Effect of thiazolidinedione use on lipid levels [abstract]. Diabetes 2003;52(Suppl 1):515P
   Google Scholar
• Tan SA, Tan LG, Berk LS. Comparative study of the effects of rosiglitazone and ACTOS on interferon-[gamma], tumor necrosis factor, interleukin-1[beta], interleukin-4, interleukin-6 and c-reactive protein in diabetic patients with atherosclerosis [abstract]. Diabetes 2002;51\(Suppl 2):A595
   Google Scholar
• Davidson PC, Sabbah HT, Steed RD, Richardson P, Robertson DG, Bode BW. Pioglitazone versus rosiglitazone therapy in randomized follow-up in patients previously treated with troglitazone [abstract]. Diabetes 2001;50(Suppl 1):A109
   Google Scholar
• Rosenblatt SI, Yoder CL, Albert JE, et al. Actos vs. Avandia: comparison of conversion from Rezulin on significant clinical parameters [abstract]. Diabetes 2002;51(Suppl 2):A143
   Google Scholar
• Buse J, Harmel AP, Kendall D, et al. Attenuating cardiovascular disease risk factors in patients with type 2 diabetes with metformin, sulfonylureas, and thiazolidinediones [abstract]. Diabetes 2003;52(Suppl 1):1919
   Google Scholar
• DeRosa G, Mugellini A, Ragonesi PD, et al. Comparison between glimepiride plus ACTOS vs. glimepiride plus rosiglitazone on glucose metabolism and on lipid, lipoprotein and apolipoprotein fractions in type 2 diabetic patients [abstract]. Diabetes 2003;52\(Suppl 1):A458–A459
   Google Scholar
• LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18(6):363–70
   PubMed Web of Science ®Google Scholar
• King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones [letter]. Diabetes Care 2000;23:557
   PubMed Web of Science ®Google Scholar
• Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708–11
   PubMed Web of Science ®Google Scholar
• Peters Harmel AL, Kendall DM, Buse JB, Boyule PJ, Marchetti A, Lau H. Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004;20(2):215–23
   PubMed Web of Science ®Google Scholar
• Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J. Effects of ACTOS and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes: a retrospective review of randomly selected medical records. Clin Ther 2002;24: 378–96
   Google Scholar
• Gegick CG, Altheimer MD, Kissling GE. Benefits of computerized outcome analysis in diabetes management. Endocr Pract 2000;6:253–9
   Google Scholar
• Lipitor package insert. NY, NY 10017: Pfizer Parke-Davis, April 2002
   Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339: 229–34
   Google Scholar
• May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449–52
   PubMed Web of Science ®Google Scholar
• Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2001;135:306
   PubMed Web of Science ®Google Scholar
• Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000;132:118–21
   PubMed Web of Science ®Google Scholar
• Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. Ann Intern Med 2000;32:121–4
   Web of Science ®Google Scholar
• Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27:305–13
   PubMed Web of Science ®Google Scholar
• Sakamoto J, Kimura H, Moriyama S, et al. Activation of human perioxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704–11
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 2003;9(5):406–16
   Google Scholar
• Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003;26:3148–52
   PubMed Web of Science ®Google Scholar
• Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22(2):288–93
   PubMed Web of Science ®Google Scholar
• Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002;25:542–9
   PubMed Web of Science ®Google Scholar
• Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes. Diabetes Care 2003;26(11):2983–9
   Google Scholar
• Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003;78:1088–91
   PubMed Web of Science ®Google Scholar
• Bertoni AG, Tsai A, Kasper EK, Brancati FL. Diabetes and idiopathic cardiomyopathy. Diabetes Care 2003;26:2791–5
   PubMed Web of Science ®Google Scholar
• Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff EC. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699–703
   PubMed Web of Science ®Google Scholar
• Sutton MSJ, Rendell M, Dadona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058–64
   PubMed Web of Science ®Google Scholar
• Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Whitcomb RW, The Troglitazone Study Group. Cardiac and glycemic benefits of troglitazone treatment in NIDDM [Abstract]. Diabetes 1997;46:433–9
   Google Scholar
• Tsuyuki RT, McKelvie RS, Arnold JMO, et al. Acute precipitants of congestive heart failure exacerbations. Arch Intern Med 2001;161:2337–42
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. (Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group). Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New Engl J Med 1999;341:410–8
   Google Scholar
• van Wijk JPH, de Koning EJP, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744–9
   PubMed Web of Science ®Google Scholar